Key clinical point: Administering the protease inhibitor nelfinavir concurrently with chemoradiotherapy resulted in promising local control and overall survival in patients with unresectable, locally advanced non–small cell lung cancer.
Major finding: The strategy yielded median progression-free survival of 11.7 months, median survival of 41.1 months, and cumulative local failure incidence of 39%.
Study details: An analysis of a prospective, open-label, phase 1/2 study including 35 patients with stage IIIA/IIIB non–small cell lung cancer.
Disclosures: Support came from grants from the National Institutes of Health and Abramson Cancer Center, and an American Society for Radiation Oncology training award to Dr. Rengan. Study authors reported disclosures related to Pfizer, 511 Pharma, Progenics Pharmaceuticals, Siemens, Actinium, AstraZeneca, Merck, Bristol-Myers Squibb, and others.
Rengan R et al. JAMA Oncol. 2019 Aug 22. doi: 10.1001/jamaoncol.2019.2095.